Why the study?
Despite standard-of-care anticoagulation therapy for atrial fibrillation, recrudescent cardioembolic events may still arise, particularly in elderly patients.
Case Report (n=1)
No
The presence of the FLT3-D835 mutation in blastic plasmacytoid dendritic cell neoplasm may indicate a highly aggressive phenotype with early relapse.
Atrial fibrillation (AF) is the most common type of treated heart arrhythmia. Generally, the treatment goals for atrial fibrillation are to reset the rhythm or control the rate and prevent the development and subsequent embolization of atrial thrombi. These thromboembolic events can occur with any kind of atrial fibrillation that is paroxysmal, persistent or permanent. In patients who are candidate for anticoagulation therapy, major practice guideline provides vitamin K antagonist (VKA) oral anticoagulant and non-VKA oral anticoagulants as treatment options. The risk of AF increases with age and despite treatment on standard of care anticoagulation therapy, recrudescent cardioembolic events may still arise especially in the elderly as we will see in this case.
No takes yet. Share an insight, caveat, or question.
Ebai et al. (2021) conducted a case report in Blastic plasmacytoid dendritic cell neoplasm (BPDCN) (n=1). Dose adjusted acute lymphoblastic leukemia induction regimen and DeVIC protocol was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: